|
|
Article: Gilead Sciences Announces Fourth Quarter and Full Year 2002 Financial Results; Full Year Product Sales of $424 Million, Up 122 Percent over 2001; Net Income of $72 Million for 2002.
- Article from:
- Business Wire
- Article date:
- January 30, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 30, 2003
Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the fourth quarter ended December 31, 2002. Total revenues for the fourth quarter were $145.0 million, up 95 percent, compared to total revenues of $74.3 million for the fourth quarter of 2001. Net income for the fourth quarter 2002 was $35.5 million, or $0.17 per diluted share. This compares to net income in the fourth quarter 2001 of $131.6 million, or $0.62 per share, which included a one-time non-operating gain of $157.8 million from the sale of oncology assets and related ...
Related newspaper, magazine, and journal articles:
|